Selective GIP Receptor Agonist Peptides for Diabetes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current peptidic compounds used for treating diabetes and obesity have limited half-life in vivo, require high doses to achieve selective GIP receptor activation, and can have antagonistic effects on the GLP-1 receptor, leading to gastrointestinal side effects like nausea and vomiting.
Innovation Solution
Development of novel exendin-4 derived peptides with specific structural modifications that selectively activate the GIP receptor with high affinity and selectivity over the GLP-1 receptor, enhancing stability and solubility, and combining these with GLP-1 receptor agonists for improved therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If current peptidic compounds are used to treat diabetes and obesity, then glucose control is achieved, but the half-life in vivo is limited
Solution Approach 1:
The patent applies parameter changes by systematically modifying amino acid residues at specific positions (1, 2, 7, 12, 13, 15, 16, 17, 18, 19, 20, 21, 27, 28, and 29) in the exendin-4 peptide sequence to optimize both half-life and therapeutic efficacy. These structural parameter modifications enable the peptide to resist degradation while maintaining or enhancing GIP receptor activation.
Solution Approach 2:
The invention creates composite peptide structures by combining modified exendin-4 backbone with selective GIP-receptor interacting residues, resulting in a hybrid molecule that exhibits both prolonged stability and high receptor selectivity. The composite structure integrates features from different peptide families to achieve dual optimization of pharmacokinetic and pharmacodynamic properties.
2Reliability
If high doses are used to achieve selective GIP receptor activation, then receptor activation is enhanced, but antagonistic effects on the GLP-1 receptor occur
Solution Approach 1:
The patent applies local quality by making specific amino acid substitutions at key positions (particularly 1, 2, 7, 12, 13, 15, 16, 17, 18, 19, and 20) that locally enhance GIP receptor binding affinity and selectivity. These localized modifications create high-affinity interaction zones that preferentially engage GIP receptor without triggering GLP-1 receptor antagonism, even at therapeutic doses.
Solution Approach 2:
The invention converts the potential harm of GLP-1 receptor antagonism into benefit by strategically positioning amino acid modifications that actively prevent GLP-1 receptor binding while enhancing GIP receptor selectivity. The modified peptide structure is designed to exploit subtle differences in receptor binding pockets, turning what could be cross-reactivity into selective advantage.
3Reliability
If peptidic compounds are administered, then glucose levels are lowered, but gastrointestinal side effects like nausea and vomiting occur
Solution Approach 1:
The patent extracts and removes the problematic GLP-1 receptor agonist activity from the peptide structure while retaining and enhancing GIP receptor selectivity. By taking out the amino acid sequences responsible for GLP-1 receptor interaction and replacing them with GIP-selective motifs, the invention eliminates the source of gastrointestinal side effects while preserving glucose-lowering efficacy through pure GIP receptor activation.
4Reliability
If structural modifications are made to exendin-4 to enhance GIP receptor selectivity, then receptor selectivity is improved, but solubility and stability may be affected
Solution Approach 1:
The patent carefully balances parameter changes in amino acid substitutions to improve receptor selectivity while maintaining solubility and stability. Modifications at positions 1, 2, 7, 12, 13, 15, 16, 17, 18, 19, 20, 21, 27, 28, and 29 are selected to enhance GIP receptor binding without introducing hydrophobic clusters or structural features that would compromise solubility. The invention monitors and optimizes physicochemical parameters alongside pharmacological activity.
Data Source
AI summary
New peptides as selective GIP receptor agonists The present invention relates to peptidic selective GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, hyperglycemia, as well as the treatment of disorders associated with nausea and vomiting.